Article thumbnail

Effects of different antidepressant treatments on the core of depression

By Thomas C. Baghai, Daniela Eser and Hans-Jürgen Möller

Abstract

Core symptoms of depression are a combination of psychological and somatic symptoms, often combined with psychomotor and cognitive disturbances. Diagnostic classification of depression including the concepts of melancholic, endogenous, or severe depression describe severely depressed patients suffering from most of the core symptoms, together with clinical characteristics of a cyclic unipolar or bipolar course, lower placebo response rates, higher response rates to electroconvulsive therapy, to antidepressant treatments with dually or mixed modes of action, or to lithium augmentation. Higher rates ofhypothalamic-pituitary-adrenal axis hyperactivity and specific electroencephalograph patterns have also been shown in this patient group. Summarizing the symptomatology of depression in these patients, a broad overlap between the abovementioned subgroups can be suggested. Because the positive diagnosis of those core symptoms of depression may include clinical consequences, it would be of use to integrate all the mentioned concepts in the upcoming new versions of the diagnostic systems DSM-V and ICD-11

Topics: Pharmacological Aspects
Publisher: Les Laboratoires Servier
OAI identifier: oai:pubmedcentral.nih.gov:3181885
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). [Elements for the effective treatment of patients with depressive disorders at the primary care level]. MMW Fortschr Med.
  2. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
  3. [New insights into the pathogenesis and pathophysiology of depression]. Nervenarzt. 2007;78(suppl 3:531-547.Pharmacological aspects
  4. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].
  5. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders].
  6. [Recurrent brief depressive episodes. Epidemiology, clinical aspects, diagnosis and therapy].
  7. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression.
  8. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder.
  9. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life.
  10. A double-blind trial of bupropion versus desipramine for bipolar depression.
  11. A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs amisulpride in the treatment of dysthymia.
  12. A neurotrophic model for stress-related mood disorders. Biol Psychiatry.
  13. A new depression scale designed to be sensitive to change.
  14. A proposed new approach to the clinical subclassification of depressive illness.
  15. (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry.
  16. A rating scale for depression.
  17. (2001). American Psychiatric Association Committee on Electroconvulsive Therapy:
  18. (1990). Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression.
  19. (1999). An international study of the relation between somatic symptoms and depression.
  20. (2003). An option for the primary care treatment of depressive patients? Eur Arch Psychiatry Clin Neurosci.
  21. Antidepressant effects of light in seasonal affective disorder.
  22. Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study.
  23. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.
  24. (2005). Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression. Ann Clin Psychiatry.
  25. (1999). Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry.
  26. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials.
  27. (2005). Antidepressants for neuropathic pain. Cochrane Database Syst Rev.
  28. Are all antidepressants really the same? the case of fluoxetine: a systematic review.
  29. (1996). Are benzodiazepines antidepressants? Psychopharmacology (Berl).
  30. (2000). Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision.
  31. Atypical antipsychotics for bipolar disorder.
  32. (2007). Atypical depression: current status and relevance to melancholia. Acta Psychiatr Scand.
  33. (1992). Catatonia and DSM-IV. Convuls Ther.
  34. Catatonia in depression: prevalence, clinical correlates, and validation of a scale.
  35. Catatonia in psychiatric classification: a home of its own.
  36. (2006). Clinical and demographic factors associated with DSM-IV melancholic depression. Ann Clin Psychiatry.
  37. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D.
  38. (1999). Comparison of the diagnosis of melancholic and atypical features according to DSM-IV and somatic syndrome according to ICD-10 in patients suffering from major depression. Eur Psychiatry.
  39. Defining melancholia: the primacy of psychomotor disturbance.
  40. Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences.
  41. Do many patients with depression suffer from bipolar disorder?
  42. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci. 2006;256:1-16.Pharmacological aspects
  43. Does almost everybody suffer from a bipolar disorder?
  44. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression.
  45. Dual monoamine modulation for improved treatment of major depressive disorder.
  46. ECT in the treatment of the catatonic syndrome.
  47. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther.
  48. Efficacy of milnacipran in patients with fibromyalgia.
  49. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
  50. Electroconvulsive therapy in melancholia: the role of hippocampal neurogenesis.
  51. (2007). Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol.
  52. (1992). Facet theoretic analysis of the Hamilton-D scale.
  53. for Clinical Excellence. Depression: management of depression in primary and secondary care. Available at: www nice org uk/pdf/CG023quickrefguide pdf.
  54. Hypericum perforatum--a review of clinical studies.
  55. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants.
  56. (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med.
  57. (1990). Is catatonia a primary indication for ECT? Convuls Ther.
  58. (1998). John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry.
  59. (1994). Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. Eur Arch Psychiatry Clin Neurosci.
  60. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression.
  61. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms.
  62. (1997). Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Int Clin Psychopharmacol.
  63. Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidity and personality. Acta Psychiatrica Scandinavica.
  64. (1994). Nemeroff CB. Contemporary management of depression.
  65. Neuroimaging studies of mood disorders.
  66. (2002). New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol.
  67. of Mental Health. 028 CGI. Clinical Global Impressions.
  68. One-year follow-up after successful ECT: a naturalistic study in depressed inpatients.
  69. (1992). Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organization;
  70. Phaseshifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf).
  71. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol.
  72. (2000). Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr Psychiatry.
  73. (1996). Psychotic depression. J Clin Psychiatry.
  74. Recurrent brief depression revisited. Int Rev Psychiatry.
  75. Reevaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders.
  76. Resurrecting melancholia.
  77. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.
  78. (2007). Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol.
  79. Short term treatment of mood disorders with standard antidepressants.
  80. Sleep and circadian rhythms in mood disorders.
  81. Somatic symptoms, depression, and antidepressant treatment.
  82. (1998). SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety.
  83. Suicidal tendencies as a complication of light therapy for seasonal affective disorder: a report of three cases.
  84. (2002). Synaptic plasticity and mood disorders. Mol Psychiatry.
  85. The doctrine of the two depressions in historical perspective. Acta Psychiatr Scand.
  86. The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum.
  87. (1990). The effects of phototherapy in the general population.
  88. (2007). The facets of melancholia. Acta Psychiatr Scand.
  89. The Ham D is more homogenous and as sensitive as the Ham D. Eur Psychiatry.
  90. (1981). The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand.
  91. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression.
  92. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy.
  93. The treatment of psychotic depression.
  94. (1985). The Zurich Study-a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. IV. Recurrent and nonrecurrent brief depression. Eur Arch Psychiatry Neurol Sci.
  95. (2006). Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res.
  96. Treatment response in melancholia.
  97. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.
  98. When do antidepressants worsen the course of bipolar disorder?
  99. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol.
  100. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression.